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1, INTRODUCTION 
Recently, Miyata et al. isolated from ovine 
hypothalamus two amidated peptides named, respec- 
tively, Pituitary adenylate cyclase activating polypep- 
tide with 38 residues (PACAP-38) [l] and the N- 
terminal amidated 27-residue derivative (PACAP-27) 
[2,3]. PACAP- is 68% similar to VIP. PACAP- 
and PACAP- show high affinity for VIP receptors in 
membranes from lung [4], pancreas [S] and liver [6] 
from rat, and for helodermin-preferring receptors in 
the human lymphoblastic cell line SUP-T1 ([7] and 
Gourlet et al., unpublished data). In addition, 
PACAP- and PACAP- interact also with highly 
selective PACAP receptors of rat central nervous 
system [4,8,9], cultured rat astrocytes [lo], human 
neuroblastoma cells NB-OK [1 11, rat adrenochromaffin 
cells [ 121, and rat cancerous pancreatic acinar cells AR 
2. MATERIALS AND METHODS 
ADbrevialions: PACAP- and PACAP.27, pituitary adcnyiate 
cyclase activating polypcptides in, respectively, the long version (the 
amidatcd 38.residue peptide(l-38)) and the N-terminal amidated 
27.residue derivative version(l-27); VIP, vasoactive intestinal pcp- 
tide; rat PHI and PHV, rat peptidc histidine-isolcucinamide(l-27) 
and rat peptide histidinc valinamidc(l-44) 
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2.1 I Cell cuirure and crude membrane preparation 
The pancreatic acinar cell line AR 4-25 was cultured as described 
[13], For membrane preparation, cells were mechanically detached, 
washed with fresh culture medium, pelleted at SO x g for 10 min, 
tysed in hypotonic 1 mM NaHCO3 and quickly frozen in liquid Nz. 
The lysatc was then defrosted, centrifuged at 4“C for IO min at 
2000 x g and the supernntant was centrifuged for IO min at IS000 x 
g. The pellet was rcsuspcndcd in I mM NaHCOJ it) order to obtain a 
protein concentration of approximately 2OO/~g/ml and immediately 
tested. 
+ Pre~errr uddws: INSEHM U-t 51, CHU liongueil, Toulouse, PACAP- and PACAP(G-27) were rynthcsiscd by solid phase 
France technique on an Automated Applied Diorystems apparatus (Foster 
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The existence of specific receptors for the two PACAPs (Pituirary Adenylate Cyclasc Activating Peptides of 27 and 38 amino acids) was previously 
demonstrated on membranes from the pancreatic acinar cell line AR 4-25 (Buscail et al., FEBS Lett. 202, 77-81, 1990) by [12sI]PACAP-27 binding. 
Here we demonstrate, by comparing Scatchard analysis of saturation curves and competition binding curves obtained with pzsI]PACAP-27 and 
r*sI]PACAP-38 as radioligands, the coexistence of two classes of receptors : I/ PACAP-A receptors that recognize PACAP- and PACAP- 
with the same high affinity (& 0.3 nM) and 2/ PACAP-B receptors that recognize PACAP- with a high affinity (& 0.3 nM) and PACAP- 
with a lower affinity (& 30 nM). These two receptors are coupled to adenylate cyclase but can be clearly distinguished by the ability ofPACAP(G-27) 
to specifically inhibit PACAP- adenylate cyclase activation. 
Pituitary adenylate cyclase activating polypeptide (PACAP) receptor; Adenylate cyclase; Rat pancreatic acinar cell line AR 4-25 
4-25 1131. These PACAP receptors are labelled by 
[12s1]PACAP-27, show almost equivalent affinity for 
PACAP- and PACAP- (&i 0.2-0.4 nM), 
recognize VIP at high concentration only (Kd around 
3 PM), and are positively coupled to adenylate cyclase. 
In the present study, we compared the binding pro., 
perties of [1251]PACAP-27 and [12’I]PACAP-38 on AR 
4-25 pancreatic ell membranes. Our data suggest that 
PACAP-38, besides the previously described 
PACAP- receptor [133, interact also with a second 
binding site more selectively for the longer PACAP 
form. Indeed, the fragment PACAP(6-27) inhibited 
the PACAP-27-stimulated but not the 
PACAP-38-stimulated adenylate cyclase activity, 
allowing a clear functional discrimination between 
PACAP- receptors and PACAP- receptors. 
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City, CA, USA) using the Fmoc strategy [5]. Their conformity was 
established by both total amino acid composition and Edman 
degradation. PACAP- and VIP were obtained from Novabiochem 
(Liiufelfingcn, Switzerland). 
2.3. Pepride radioiodination 
PACAP- was radioiodinated by the chloramine-T method and 
purified by HPLC as described [13]. PACAP- was labelled by the 
iodogen technique [14], then purified by HPLC under conditions 
similar to those used for PACAP-27. Four radioactive peaks were 
separated in these conditions. The first two peaks were separated 
from unlabellcd PACAP- and were equally able to specifically bind 
to membranes. The last two peaks bound poorly and with a high non- 
specificcomponent. Although the precise nature of each peak was not 
established, the two first peaks were likely to be monoiodinated forms 
of PACAP-38. These two peaks were pooled and stored in 10 mM 
sodium phosphate buffer (pH 7.4) containing 150 mM NaCI, 1.5% 
(w/v) bovine serum albumin andO.l% (w/v) Tween 20. Their specific 
radioactivity was typically 2 mCi/nmol. 
2.4, Binding studies 
Binding was conducted as previously described [I 1,131. Briefly, AR 
4-23 cell membranes were incubated at 37°C in a total volume of 
0.12 ml containing 50 mM Tris-maleate (pH 8.0). 5 mM MgClz, 
1 .O% (w/v) bovine serum albumin, 100 KIU/ml Trasylol, 0.5 m&ml 
bacitracin, and [‘251]PACAP-27 or [‘2Sl]PACAP-38 (0.05 nM under 
standard binding conditions). Non-specific binding of 
[1251]PACAP-27 and (‘251]PACAP-38 was determined in the presence 
of, respectively, 0.1 pM PACAP- and 0.1 PM PACAP-38. The 
separation of membrane bound and free radioactivities was achieved 
by rapid filtration through glass-fiber filters @F/C, Whatman, 
Maidstone, Kent, UK) presoaked for 24 h in 0.1% po- 
ly(ethyleneimine) followed by rinsing with a 0.1 M phosphate bufler 
(pH 7.4) containing 1% (w/v) bovine serum albumin. 
2.5. Adenylate cyclase assay 
The assay was performed as previously described, at 37”C, in the 
presence of 0.1 pM GTP, and in a final volume of 0.06 ml [15,16]. 
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Fig. 1. Asaociution (A) and dissociation (B) kinetics of 
[“SI)PACAP-27 and [“sl]PACAP-38 on rat pancreatic At? 4.25 ccl1 
ttxmbritncs 81 37T. Specific binding of [“.‘I]PACAP.27 (co) arid 
(“SIJPACAP~31 (0) was expressed in % of chc vulue obtnined eftcr 8 
30 ndn incubation of each tracer. (‘zLL)PACAP*27 and 
(“J1]PACAP.38 dissochion wa l~rduccd by addlog, after it 30 tnin 
prcitrcubotion with wtwr, 1 &I PACAP- and i pM PACAP-38, 
rexpcctivety. Keaultr wwc !Re nren~la of experiments pcrformcd in 
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Fig. 2. Scatchard transformation of saturation curves of 
[‘251]PACAP-27 and [‘251]PACAP-38 binding to rat pancreatic AR 
4-25 cell membranes. B,,,,, was expressed in pm01 of ligand bound * mg 
protein-’ and F as pM, Values were the means of experiments 
performed in duplicate on 3 different membrane preparations. 
3. RESULTS 
[‘*‘I]PACAP-27 and [?]PACAP-38 bound rapid- 
ly, specifically and reversibly (by 40% after 15 min, the 
longest period tested), at 37’C, to AR 4-25 cell mem- 
branes (Fig. 1). Saturation curves (Fig. 2) performed 
with increasing concentrations of both tracers were 
compatible with the labelling, by each tracer, of one 
homogeneous class of binding sites. The total number 
of binding sites labelled by [‘2SI]PACAP-38 and 
[“‘I]PACAP-27 was, respectively, 1.2 k 0.2 and 0.6 tt 
0.1 pmol . mg prot:’ (means + SE of 3 experiments), 
and the corresponding Kd values were, respectively, 
0.23 + 0,03 nM and 0.40 f 0.05 nM. 
[‘*‘I]PACAP-27 binding was inhibited dose- 
dependently by PACAP-27, PACAP-38, and related 
peptides with the following decreasing order of poten- 
cy: PACAP- > PACAP- > PACAP(6-27) 2 VIP. 
The inhibition curve of [‘2SI]PACAP-27 binding by 
unlabellcd PACAP- was flatter than with 
PACAP-38, and PACAP(6-27) was 300.fold less po- 
tent that1 PACAP(f -27) (Fig. 3). 
[“‘I]PACAP-38 binding was totally inhibited by 
unlabcllcd PACAP-38. PACAP- was 30.fold less po- 
tent in this respect han PACAP-38, baaed on the tC,n 
value, Furthermore, the slope of the competition curve 
of [‘2sI]PACAP-38 binding by PACAP- indicated 
that PACAP- recognized one class of binding sites 
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Fig. 3. Dose-effect CLIWCS of inhibition of [‘2Sl]PACAP-27 (upper 
panel) and [‘2S1]PACAP-38 (lower panel) binding to rat pancreatic 
AR 4-25 cell membranes by PACAP- (e), PACAP- (O), 
PACAP(6-27) (A) and VIP (A). Results were the means of 
experiments performed in duplicate on 3-5 different membrane 
preparations. 
(Hill coefficient of 0.92 Z!Z 0.06; mean f SD; n = 3) and 
PACAP- recognized more than one class of sites (Hill 
coefficient of 0.52 & 0.02). This statistical analysis was 
further confirmed using the fitting program of Munson 
and Rodbard [17]. The probability that a two-site 
model was not better than a one site model for 
PACAP- was only 0.0001. The best fit for a two-site 
model was obtained considering the coexistence of 63 k 
4% of sites with a Kd of 6.7 k 1.5 nM and 25 Z!Z 4% of 
sites with a &I of 890 jz 410 nM (means k SE). A 
statistical analysis of a three-site model could not be 
performed. The 1% of PACAP(6-27) was loo-fold 
higher than that of PACAP- and this fragment in- 
hibited [12sI]PACAP-38 binding IO-times less potently 
than [1251]PACAP-27. VIP at 1 PM inhibited 
[‘2SI]PACAP-38 binding by 10% only, 
Confirming our previous data [13], PACAP- and 
PACAP- stimulated adenylate cyclase with the same 
efficacy, PACAP- being 3-fold less potent than 
PACAP- (Fig. 4). PACAP(6-27) exerted no 
stimulatory effect but inhibited the stimulated enzyme 
competitively, when given in combination with 
PACAP(l-27). Coupling data in Figs, 4 and 5, the Ki 
for PACAP(G-27) on the PACAP-27-stimulated en- 
zyme can be estitntited as 500 f 50 nM (mean f SE of 
5 experitnents), a value similar co the I&e value of this 
1 1004 i 
J?-fl. . . . * 7 *l-II. . . 7 
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Fig. 4. Dose-effect curves of adenylate cyclase activation by 
PACAP- (left panel) and PACAP- (right panel). in the presence 
of 0.1 ,uM CTP and in the absence (0) or presence (0) of 3 /IM 
PACAP(6-27). Results were expressed in pmol cyclic AMP 
produced -min-’ * mg protein-’ and were the means of experiments 
performed in duplicate on 3 different membrane preparations. 
fragment on [i2’I]PACAP-27 binding (Fig. 3). In con- 
trast, the inhibition of the PACAP-38-stimulated en- 
zyme, in the combined presence of 10,uM 
PACAP(6-27) and 0.1 nM PACAP-38, was weak and 
did not exceed 4Oolo: the Ki of PACAP(6-27) on 
PACAP-38-stimulated adenylate cyclase could not be 
calculated accurately but appeared to be higher than 
3 PM (Fig. 5). 
4. DISCUSSION 
Four arguments upport the view that at least two 
classes of selective PACAP receptors coexist in rat pan- 
sreatic AR 4-25 membranes: (i) the total number of sites 
labelled by [“‘I]PACAP-38 was two-fold higher than 
that Iabelled by [i2’I]PACAP-27; (ii) PACAP-38, 
PACAP-27, PACAP(6-27) and VIP inhibited 
[‘251]PACAP-27 and [‘251]PACAP-38 binding with dif- 
ferent rank of potencies; (iii) inhibition curves of tracer 
binding with PACAP- were flatter than those ob- 
tained with PACAP-38; (iv) PACAP(6-27) inhibited 
f-l- J 
0.3 1.0 3,o 10.0 
(PACAP (6-27) 
+ 0.3 nM 
PACAP (l-38) 
clh----------l 
0.3 1.0 3.0 !3. 
I (UM) 
0 
Pig. 5, Inhibition by increasing PACAP(G-27) concentrations of 
adcnylatc cyrlase stimulation by different concentrations of 
PACAP- (left panel) or PACAP- (right panel). The results were 
cxprcssed in % of udenylatc yclnse activity without PACAPW27), 
nftrr subtraction of the basal value and were the means of 
cxpcrimcn~s performed in duplice~c on 3 different membrarre 
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PACAP-27.stimulated adenylate cyclase more potently 
than the PACAP-384mulated enzyme. 
Thus, a first class of PACAP-A receptors seemed to 
recognize PACAP- and PACAP- with the same 
high affinity (0.3 nM) and VIP with low affinity. 
PACAP- stimulation of adenylate cyclase through 
these receptors was inhibited by PACAP(6-27) with a 
Ki of 500 nM. The second class of PACAP-B receptors 
recognized PACAP- with high affinity (0.3 nM), 
PACAP- with lower affinity (ICSO 30 nM), and was 
virtually unable to recognize VIP. PACAP- stimula- 
tion of adenylate cyclase occurred essentially through 
this class of receptors as it was only weakly inhibited by 
PACAP(6-27). Therefore, PACAP- recognized 
PACAP-A and PACAP-B receptors equally well but 
appeared to activate adenylate cyclase through 
PACAP-B receptors only: this could be due to a higher 
density of PACAP-B receptors and/or to more efficient 
receptor-Gs coupling. 
PACAP- and PACAP- coexist in mammalian 
tissues [ 1,3] and derive from the same precursor [l-3]. 
Their processing remains to be established and, by 
analogy with the glucagon system [ 181, both PACAPs 
may conceivably result from independent, tissue- 
specific, cleavage rather than from successive cleavage 
involving PACAP- as a PACAP- precursor. The 
presence of distinct receptors for different molecular 
forms of biologically active peptides has already been 
documented: for instance, glucagon and oxyn- 
tomodulin (a C-terminally extended form of glucagon) 
act on diverse receptors in several tissues and exert dif- 
ferent physiological functions [19,20]. This is by no 
means a general rule as, by way of another example, the 
three different molecular forms of rat PHI (PHI, PHI- 
glycine and PHV [21,22]) bind to the same receptors 
[231. 
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